Drug Trial Radar · NCT06305247
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
36
Actual
Start
Apr 3, 2024
Primary completion
Mar 20, 2028
Study completion Mar 20, 2028
Sponsor
- Lead sponsor
- IpsenIndustry
- Sponsor type
- Industry
- First posted
- Mar 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body. In this study, all participants will receive the study drug, which will be taken by mouth (orally).
Conditions
- Melanoma
- Head and Neck Squamous Cell Carcinoma
- Pancreatic Ductal Adenocarcinoma
- Colorectal Cancer
- Solid Tumor
Interventions
IPN01194Drug
IPN01194 will be taken orally over a period of 28 days (a "Cycle") at the assigned dose level. The dose limiting toxicity (DLT) observation period consists of the first 28 days of treatment with IPN01194 (Cycle 1). Participants will receive IPN01194 treatment beyond Cycle 1 until treatment is precluded by toxicity, disease progression, or upon participant's request or investigator decision.
IPN01194Drug
All participants will receive IPN01194 orally for 28-day cycles at one of the two dose levels determined at the end of Phase I. Participants will receive IPN01194 treatment until treatment is precluded by toxicity, disease progression, or upon participant's request or investigator decision
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Percentage of participants with dose limiting toxicity (DLT)Time frame: Within 28 days of first dose
- Phase 1: Percentage of participants experiencing Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TE SAEs)Time frame: At 30 days following the last administration of study intervention
- Phase 1: Percentage of participants with dose interruptions and permanent treatment discontinuationsTime frame: At 30 days following the last administration of study intervention
- Phase 2a: Objective response rate (ORR)Time frame: At end of treatment (up to approximately 32 months)
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
The Angeles Clinic and Research Institute - California
Los Angeles, California
UC San Diego Health System - La Jolla
San Diego, California
Yale Cancer Center - New Heaven
New Haven, Connecticut
Sarah Cannon Research Institute (SCRI) - Nashville
Nashville, Tennessee
Virginia Cancer Specialist
Fairfax, Virginia
Centre Léon Bérard - Lyon
Lyon, France
Paris Saint-Louis
Paris, France
Institut de Cancerologie de l'Ouest (St-Herblain)
Saint-Herblain, France
IGR-Villejuif
Villejuif, France
Barcelona - Val D'Hebron
Barcelona, Spain
Fundacion Jimenez Diaz - Madrid
Madrid, Spain
M.D. Anderson Cancer Center Madrid
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.